Dosing Research

Question 1

When should I start PCT after my last Testosterone Enanthate injection?

Accepted Answer

Day 14 post-last-injection. That is the answer. The reasoning matters — it drives how you handle short esters, mixed cycles, and 19-nors with entirely different kinetics. The kinetics Testosterone Enanthate: t½ ≈ 4.5 days IM. Five half-lives to reach functional clearance. Serum concentrations at post-last-injection intervals: Day 7: 50% of peak still circulating Day 14: 25% — SERM signalling begins to register at the pituitary Day 21: 6–12% — effectively baseline for recovery purposes Starting SERMs at day 7 is wasted medication — the hypothalamus still reads suppressive androgen load and will not resume GnRH pulsing. Starting at day 21 leaves an additional week of HPTA inactivity before recovery stimulus arrives. Day 14 is the compromise the published protocols converge on. Cypionate t½ 8 days. The 14-day rule holds; some conservative protocols extend to day 16–18. The difference is negligible. Short esters — Propionate, Trenbolone Acetate Propionate t½ is 0.8&hellip;

Question 2

What is the typical Testosterone Enanthate dose in clinical research?

Accepted Answer

The clinical literature spans replacement-dose protocols (100 mg/week — restoring low-end-normal serum testosterone in primary hypogonadism) to supraphysiological investigation arms (600 mg/week — measuring upper-end anabolic response in healthy controls). The landmark dose-response data come from two Bhasin studies that established the framework still used today. TRT / hypogonadism restoration — the lower bound Replacement protocols in the published endocrinology literature: 100–200 mg testosterone enanthate per 1–2 weeks. The Bhasin 1996 reference arm used 100 mg/week, producing serum total testosterone in the 500–800 ng/dL range — mid-reference for adult males. This is the dose that puts back what the body stopped making, without exceeding physiological signal. Clinical TRT in current practice has shifted toward higher cadence (twice-weekly 50–80 mg dosing) and slightly higher weekly totals (140–200 mg/week) to maintain serum testosterone in the 700–1000 ng/dL range, which produces better symptomatic response than mid-reference. Supraphysiological / hypertrophy research — the published&hellip;

Question 3

How do I titrate clenbuterol without crashing my heart rate?

Accepted Answer

Clenbuterol is a long-acting β2-adrenergic agonist. At therapeutic doses it is β2-selective, driving cAMP elevation in bronchial smooth muscle (the veterinary indication) and in adipose and skeletal muscle (the reason it is used off-label for body-recomposition protocols). Selectivity is not absolute — at supra-therapeutic doses β1 crossover produces cardiac effects that are the dominant safety concern. Pharmacokinetics that matter for titration Clenbuterol has a serum half-life of 24–36 hours in humans. This is substantially longer than most users assume and has two consequences: (1) steady-state takes 5–7 days at a fixed dose, which is why subjective effects intensify across the first week at a given mg; (2) dose changes take 48–72 hours to fully manifest, meaning rapid titration escalation overshoots before the previous step has been properly assessed. Titration schedule 40 mcg tablets split cleanly for precise titration at the start: Days 1–2: 20 mcg once daily, morning dose only.&hellip;

Question 4

When does Deca start working — is 4 weeks normal?

Accepted Answer

Yes. The question itself reveals the problem: users expect short-ester kinetics from a long-ester compound and read the ester-lag as compound failure. Four weeks to clinical effect on nandrolone decanoate is textbook, not exception. Pharmacokinetics that produce the lag Nandrolone decanoate has an IM elimination half-life of 6–12 days, driven by slow hydrolysis of the C10 decanoate ester at the oil-tissue interface. Steady-state serum concentration — the point at which weekly dosing produces a stable peak-trough curve — requires 5 half-lives of consistent administration. 5 half-lives × 6–12 days = 30–60 days to peak steady-state concentration. A 400 mg weekly dose produces serum nandrolone of 100–200 ng/mL at steady-state. At week 2 the user is reading roughly 40% of that value. At week 4, roughly 85%. Subjective effect tracks with androgen-receptor occupancy, which follows serum concentration with a short lag — so the clinical onset typically reports at week 3–5&hellip;

Question 5

What is a safe T3 dose for cutting?

Accepted Answer

Liothyronine (T3) is synthetic triiodothyronine — the biologically active thyroid hormone. At physiological concentrations it regulates basal metabolic rate through nuclear thyroid-receptor signalling and mitochondrial uncoupling-protein expression. At supra-physiological doses it drives the same pathways harder, producing fat-loss acceleration at the cost of protein catabolism, HPT-axis suppression, and dose-dependent cardiac strain. Mechanism — why T3 is not "thyroid replacement" Exogenous T3 bypasses the hepatic deiodinase conversion step that normally regulates systemic T3 availability from circulating T4. The feedback loop reads elevated T3 and suppresses TSH, which suppresses thyroid-gland T4 production. Over a 6–8 week course free T4 falls below reference range, free T3 rises above reference range, and TSH is undetectable. This is the expected picture on protocol — the concern arises at cessation. Once T3 administration stops, the thyroid gland requires 4–12 weeks to resume adequate T4 output. During that window the user experiences iatrogenic hypothyroidism: fatigue, weight regain,&hellip;

Question 6

How do I dose Anavar for a first oral cycle?

Accepted Answer

Oxandrolone is the most forgiving 17α-alkylated oral in routine use — a reputation that reflects real pharmacology (the 2-oxa substitution in the A-ring reduces hepatic burden relative to methandrostenolone or oxymetholone) but often obscures the compounds real liability profile: severe HDL suppression and substantial SHBG reduction, both of which drive downstream clinical pictures that standard AAS discourse under-weights. Structural pharmacology — why Anavar behaves differently Oxandrolone is a DHT derivative with two structural modifications: 17α-methylation (enabling oral bioavailability by blocking glucuronidation at the 17β-hydroxyl) and replacement of the A-ring carbon-2 with oxygen (the "oxa" prefix). The oxygen substitution shifts the electronic environment around the 3-keto group, reducing CYP3A4-mediated hepatic oxidation and lowering the cumulative hepatotoxicity per mg-week of exposure. The compound does not aromatise — no 19-carbon for CYP19A1 to act on — so estrogenic side effects are absent. It is not reduced by 5α-reductase because it is already DHT-derived;&hellip;